Summary:
The Trailblazer clinical research study looks to lower the risk of cognitive decline in adults at risk of Alzheimer’s disease. Participants must have intact cognitive function and exhibit typical memory, thinking, and mood behavioral patterns. Qualified patients will be randomly assigned to one of two groups, receiving either the investigational medication or a placebo. The duration of this study could be up to 4 1/2 years. Those who receive the placebo will have the ability to enroll in the open label portion of the study where they will receive guaranteed medicine. Researchers will monitor participants’ safety, immunological responses, effectiveness of the medication, and patients’ cognitive functions.
Qualified Participants Must:
• Be between the ages of 65 and 80
• Possess regular patterns of memory, thinking, mood, and behavior
Qualified Participants May Receive:
Donanemab, MRI, TICS, routine labs, immunological response labs, blood levels and cognitive function tests.